reflux esophagitis
Conditions
Interventions
test Group:Jinghua Weikang capsule
Sponsors
Tasly Pharmaceutical Group Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: ·Sign informed consent. ·Men and women are not limited ·Age 18-70 years old ·Have been diagnosed as reflux esophagitis, and had recurrence after standard treatment ; ·Upper gastrointestinal endoscopy ( within 1 year ) had reflux esophagitis. In order to facilitate the observation of treatment time and effect, this project selected Los Angeles classification as reflux esophagitis A and B grade. ·GERD questionnaire reached 8 points in patients with ·Have appropriate organs and hematopoietic function, according to the following laboratory tests ( within 1 year ) Neutrophil count ( NEUT # ) = 1.5 × 109 / L ; platelet count = 75 × 109 / L ; hemoglobin = 90g / L ; serum total bilirubin ( TBIL ) = 2 times ULN ; alanine aminotransferase ( ALT ), aspartate aminotransferase ( AST ) = 5 times ULN ; serum albumin = 29 g / L ; serum creatinine = 1.5 times the upper limit of normal ( ULN ) or creatinine clearance rate = 50 mL / min. ·Normal electrocardiogram
Exclusion criteria
Exclusion criteria: ·Patients who received antibiotics, bismuth, H2RA and PPI treatment within two weeks before the first medication ; pregnant or lactating women ; ·Patients with moderate or above depression and mental disorders ; ·Patients with dysphagia and peptic ulcer such as achalasia, esophageal cancer ; ·Patients with severe liver disease, heart disease, kidney disease, malignant tumor and alcohol dependence ; ·Those who are allergic to the drugs used in this study ; ·Patients who participated in other clinical studies within 3 months ; ·Patients who can not correctly express their complaints and have poor compliance ; ·There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the results of the study, and subjects who the researchers believe are otherwise unfit to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to recurrence;Symptoms of recurrence;safety index; | — |
Countries
China
Contacts
Public ContactZhijun Duan
The First Afiliated Hospital of Dalian Medical University
Outcome results
None listed